-
Goldman Has Buy On Pharmaceutical Product Dev. (PPDI)
Wednesday, February 9, 2011 - 8:44am | 182Goldman Sachs has a Buy rating and a $33 price target on shares of Pharmaceutical Product Dev. (NASDAQ: PPDI). In a note to clients, Goldman writes, "PPD reported FY4Q10 EPS of $0.39 (adjusted for one-timers) versus our/consensus estimates at $0.40/$0.38. Importantly, revenue of $358 million came...
-
J.P. Morgan Raises Illumina Price Target To $75 (ILMN)
Wednesday, February 9, 2011 - 8:41am | 118J.P. Morgan raised its Illumina (NASDAQ: ILMN) price target to $75 from $68 in a research report published today. In the report, J.P. Morgan states, "Coming on the heels of a successful AGBT conference last week, in which ILMN once again had a dominant presence (see our recap note for more details...
-
JP Morgan Raises PT On Illumina To $75
Wednesday, February 9, 2011 - 8:22am | 27JP Morgan has raised the price target on Illumina, Inc. (NASDAQ: ILMN) from $68 to $75 and maintains its Overweight rating.
-
Mad Money Lightning Round OT: Cramer Thinks That TRGL Should Be Bought (ICLR, ERTS, TRGL)
Tuesday, February 8, 2011 - 8:47pm | 197CNBC Mad Money's Jim Cramer said in the segment of the show called Mad Money Lightning Round OT that he would sell ICON plc (ADR) (NASDAQ: ICLR). He explained that a lot of health care companies have been sold off, and he doesn't want to be caught in that tsunami. ICON plc (ADR) (ICLR) closed flat...
-
PPD Reports Q4 EPS of $.40 vs. $.38
Tuesday, February 8, 2011 - 5:50pm | 123PPD, Inc. (Nasdaq: PPDI) today reported its financial and operating results for the fourth quarter and full year ended December 31, 2010. PPD recorded net revenue of $388.5 million for the fourth quarter of 2010, an increase of 8.7 percent over net revenue of $357.4 million for the fourth quarter...
-
PPD Announces $200M Accelerated Share Repurchase
Tuesday, February 8, 2011 - 5:49pm | 66PPD, Inc. (Nasdaq: PPDI) today announced it intends to enter into an accelerated share repurchase (ASR) agreement with Barclays Capital Inc. under which PPD will repurchase shares of its common stock. These repurchases will be made pursuant to PPD's previously announced $350 million stock...
-
CEO David L. Grange to Retire from PPD
Tuesday, February 8, 2011 - 5:47pm | 70PPD, Inc. (Nasdaq: PPDI) today announced that David L. Grange plans to retire as chief executive officer of PPD and a member of its board of directors. Grange joined PPD's board in 2003 and served with distinction as an independent director until mid-2009 when he became chief executive officer....
-
Illumina Reports Q4 EPS of $.29 vs. $.29
Tuesday, February 8, 2011 - 5:28pm | 84Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year of 2010. Revenue of $261.3 million, a 45% increase over the $180.6 million reported in the fourth quarter of 2009. GAAP net income of $38.4 million, or $0.25 per diluted share, compared to...
-
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2010: EPS of $0.25
Tuesday, February 8, 2011 - 5:10pm | 110Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year of 2010. Fourth quarter 2010 results: * Revenue of $261.3 million, a 45% increase over the $180.6 million reported in the fourth quarter of 2009. * GAAP net income of $38.4 million, or...
-
Jefferies Lowers PT Of Albany Molecular Research To $4.50 (AMRI)
Tuesday, February 8, 2011 - 11:32am | 103Jefferies finds Albany Molecular Research's (NASDAQ: AMRI) “continued reliance on declining Allegra royalties makes profit growth difficult. An OTC conversion will extend the stream, but won't convert it to a growth driver.” The report further adds, “AMRI reported a non-GAAP 4Q loss of $0.16 on...
-
Jefferies Lowers PT On Albany Molecular Research To $4.50
Tuesday, February 8, 2011 - 9:00am | 28Jefferies & Company has lowered the price target on Albany Molecular Research (NASDAQ: AMRI) from $5.50 to $4.50 and maintains its Hold rating.
-
Luminex Corporation Reports Q4 EPS of $.06 vs. $.05
Monday, February 7, 2011 - 5:16pm | 117Luminex Corporation (Nasdaq: LMNX) today announced financial results for the fourth quarter and year ended December 31, 2010. Recent financial and operating highlights include the following: Fourth quarter 2010 consolidated revenue was $41.2 million, an 8 percent increase over the fourth quarter of...
-
Bioanalytical Systems, Inc. Reports Q1 EPS of $0.06
Monday, February 7, 2011 - 3:08pm | 174BASi (Nasdaq: BASI) today reported financial results for the first three months of fiscal 2011, ending December 31, 2010. For the quarter ended December 31, 2010, the Company reported net earnings of $310,000 ($0.06 per share, basic and diluted) on revenues of $8.1 million. This compares to a loss...
-
Piper Jaffray Provides Color On ILMN Leukemia Tumor Data
Monday, February 7, 2011 - 9:19am | 145Data from Illumina, Inc. (NASDAQ: ILMN) in leukemia tumors after deep re-sequencing found a class of mutations that were not present with the initial diagnosis, Piper Jaffray reports. “If this work is reproduced in other cancer types where we had initially expected 2-3 sequencing runs, (normal,...
-
Albany Molecular Reports Wider-Than-Expected Q4 Loss
Monday, February 7, 2011 - 8:14am | 63Albany Molecular Research Inc (NASDAQ: AMRI) reports its Q4 loss at $0.16 per share, versus the expected loss of $0.15 per share. AMRI reports its Q4 revenue at $48.6 million, versus the consensus of $47.87 million. AMRI shares gained 0.41% to close at $4.89 on Friday. Read more from Benzinga's...